Result of AGM

Venn Life Sciences Holdings Plc

(“Venn” or the “Company”)

 Result of AGM

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

Venn Life Sciences Holdings Plc
Tony Richardson, Chief Executive Officer Tel: +353 154 99 341
Paul Foulger, Finance Director Tel: 020 7245 1100
Orla McGuinness, Marketing Manager Tel: +33 (0)1 30 82 67 07
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones(Corporate Finance) Tel: 0161 831 1512
John Goold (Institutional Sales) Tel: 020 7533 7716
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation (“CRO”) providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company’s near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.